Tuesday, July, 16, 2019 04:16:42

Contribution By Ojaswita Kutepatil


Aimmune Therapeutics closes $98M Investment by Nestlé Health Science

Aimmune Therapeutics Inc., a California-based clinical-stage biopharmaceutical company, has reportedly announced that it has closed the $98 million equity investment by Nestlé Health Science. Reports cite, Nestlé Health Science bought about 3,237,529 newly issued shares of the Brisbane, California-headquartered Aimmune Therapeutics’ common stock, at a …

Quest & OncoCare to advance cancer therapy technology in the U.S.

Canadian biopharmaceutical company, Quest PharmaTech Inc., has reportedly announced its entry into a license agreement with OncoCare Therapeutics Inc., a biopharmaceutical company based in Omaha, Nebraska. According to sources, the duo has come together in a bid to develop and commercialize the targeted cancer therapy …

Sysmex, MolecularMD partner for CDx development and commercialization

Japan’s in-vitro diagnostics company, Sysmex Corp. has recently announced a collaboration agreement with U.S. molecular diagnostics firm, MolecularMD Corp., to target challenges in current and future companion diagnostics (CDx) development and commercialization for accelerating precision medicines. As per trusted sources, the non-exclusive collaboration agreement is …

Lupin launches generic Tetrabenazine tablets in the United States

Lupin Limited, a renowned transnational pharmaceutical company headquartered in Mumbai, India, has reportedly announced the launch of its Tetrabenazine tablets in the U.S. Reports cite, the drug is used to treat the involuntary moments that an individual suffering from the Huntington’s disease often experiences. The …